Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 5/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421432 | 0.77 | TDP1 (0.36) | SMN1; SMN2LMNAXDHALDH1A1HPGD | |
| SCHEMBL20213686 | 0.77 | LMNA (0.43) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL12535705 | 0.77 | PDPK1 (0.49) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL6907428 | 0.77 | LMNA (0.43) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL22292592 | 0.74 | LMNA (0.41) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL18555761 | 0.73 | BCAT2 (0.42) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL22488626 | 0.73 | CYP1A2 (0.43) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL28918223 | 0.70 | DYRK1A (0.38) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL408976 | 0.70 | DYRK1A (0.55) | TSHRSMN1; SMN2LMNARAB9ADYRK1A | |
| SCHEMBL20187560 | 0.69 | PDPK1 (0.49) | DYRK1AACHEGDAALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115768764-B | Parallel ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7715989-B2 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | ELITECH HOLDING B.V. (NL) | 2010-05-11 | — | — | US | disclosed |
| US-7715989-B2 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | ELITECH HOLDING B.V. (NL) | 2010-05-11 | — | — | US | disclosed |
| US-7715989-B2 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | ELITECH HOLDING B.V. (NL) | 2010-05-11 | — | — | US | disclosed |
| EP-1944310-A2 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7368549-B2 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368549-B2 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368549-B2 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7045610-B2 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060003349-A1 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050075491-A1 | TM leveling methods | EPOCH BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-6683173-B2 | CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER | EPOCH BIOSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030235822-A1 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | EPOCH BIOSCIENCES, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030224359-A1 | TMLEVELING METHODS | EPOCH BIOSCIENCES, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003349-A1 | Tm leveling compositions | RNGTT, TYMS, NT5C3B | TSHR 992/4885SMN1; SMN2 1408/4885LMNA 458/4885 |
| US-20050075491-A1 | TM leveling methods | RNGTT, TYMS, NT5C3B | TSHR 582/4885SMN1; SMN2 1653/4885LMNA 451/4885 |
| US-20030224359-A1 | TMLEVELING METHODS | PTBP3, RNGTT, DTYMK | TSHR 884/4885SMN1; SMN2 1537/4885LMNA 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.